High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Pipeline Review, H1 2018

  • ID: 4479939
  • Drug Pipelines
  • 40 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Affibody AB
  • Evec Inc
  • Ribomic Inc
  • MORE
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Pipeline Review, H1 2018

Summary:

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - High mobility group box 1 protein also known as high-mobility group protein 1 (HMG-1) is a protein encoded by the HMGB1 gene.HMGB1 is secreted by immune cells like macrophages, monocytes and dendritic cells through leaderless secretory pathway.

Activated macrophages and monocytes secrete HMGB1. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. Treatment includes antibodies that neutralize HMGB1 protects against damage and tissue injury during arthritis, colitis, ischemia, sepsis, endotoxemia, and systemic lupus erythematosus.

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Infectious Disease, Oncology, Cardiovascular, Hematological Disorders, Immunology, Respiratory and Toxicology which include indications Sepsis, Parkinson's Disease, Traumatic Brain Injury, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Cerebral Infarction (Brain Infarction), Chemotherapy Effects, Chronic Pain, Epilepsy, Idiopathic Pulmonary Fibrosis, Inflammation, Influenzavirus A Infections, Myelodysplastic Syndrome, Neuropathic Pain, Neutropenia, Stroke and Thrombocytopenia.

The latest report High Mobility Group Protein B1 - Pipeline Review, H1 2018, outlays comprehensive information on the High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)
  • The report reviews High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Affibody AB
  • Evec Inc
  • Ribomic Inc
  • MORE
Introduction

Report Coverage

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Overview

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Companies Involved in Therapeutics Development

Affibody AB

Cantex Pharmaceuticals Inc

Evec Inc

Ribomic Inc

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Drug Profiles

dociparstat sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit HMGB1 for Inflammation and Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit HMGB1 for Parkinson’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-007156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit HMGB1 for Influenza A Infections and Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant High Mobility Group Protein B1 Replacement for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit HMGB1 for Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSA-521 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Dormant Products

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Product Development Milestones

Featured News & Press Releases

Jan 03, 2018 : Cantex Pharmaceuticals Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia

Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia

Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-

May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting

Feb 09, 2005: ParinGenix Gets FDA Approval of IND for PGX-

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Affibody AB, H1 2018

Pipeline by Cantex Pharmaceuticals Inc, H1 2018

Pipeline by Evec Inc, H1 2018

Pipeline by Ribomic Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Affibody AB
  • Cantex Pharmaceuticals Inc
  • Evec Inc
  • Ribomic Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll